MarketCap
Facebook
X
TelegramAnnual report 2025
added 11-25-2025
Becton, Dickinson and Company Operating Income 2011-2026 | BDX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Becton, Dickinson and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.58 B | 2.4 B | 2.11 B | 2.28 B | 2.25 B | 912 M | 1.76 B | 1.51 B | 1.52 B | 1.43 B | 1.07 B | 1.61 B | 1.25 B | 1.56 B | 1.67 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.58 B | 912 M | 1.73 B |
Quarterly Operating Income Becton, Dickinson and Company
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 882 M | 546 M | 453 M | 602 M | 734 M | 439 M | 549 M | 628 M | 585 M | - | 537 M | 564 M | 692 M | - | 628 M | 434 M | 1.24 B | 1.23 B | 358 M | 1.24 B | 501 M | 1.65 B | 626 M | 501 M | 888 M | 933 M | 512 M | 888 M | 235 M | 1.04 B | -223 M | 230 M | 811 M | 1.33 B | 516 M | 811 M | 352 M | 779 M | 137 M | 352 M | 349 M | 1.2 B | 445 M | 349 M | 378 M | 1.18 B | 405 M | 378 M | 392 M | 1.17 B | 449 M | 392 M | 337 M | 1.25 B | 447 M | 359 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.65 B | -223 M | 642 M |
Operating Income of other stocks in the Medical instruments industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
22.6 K | - | - | $ 810 M |  USA |
 |
Baxter International
BAX
|
14 M | $ 20.1 | 1.85 % | $ 10.3 B | USA |
 |
ICU Medical
ICUI
|
43 M | $ 148.85 | -0.79 % | $ 3.63 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-10.5 M | $ 8.57 | 2.15 % | $ 173 M | USA |
 |
Alcon
ALC
|
580 M | $ 81.03 | -0.12 % | $ 40.4 B |  Schweiz |
 |
Repro Med Systems
KRMD
|
-10.3 M | $ 5.39 | -1.1 % | $ 246 M | USA |
 |
AtriCure
ATRC
|
-40 M | $ 36.9 | -0.14 % | $ 1.73 B | USA |
 |
Haemonetics Corporation
HAE
|
222 M | $ 66.55 | 0.88 % | $ 3.35 B | USA |
 |
electroCore
ECOR
|
-19.3 M | $ 6.6 | -7.04 % | $ 36.4 K | USA |
 |
AngioDynamics
ANGO
|
-40 M | $ 10.3 | 3.21 % | $ 421 M | USA |
 |
InfuSystem Holdings
INFU
|
1.65 M | $ 8.27 | 2.73 % | $ 171 M | USA |
 |
OraSure Technologies
OSUR
|
-28.2 M | $ 2.78 | -0.54 % | $ 207 M | USA |
 |
The Cooper Companies
COO
|
683 M | $ 81.34 | 1.21 % | $ 16.2 B | USA |
 |
Masimo Corporation
MASI
|
-267 M | $ 137.49 | 0.91 % | $ 7.33 B | USA |
 |
Harvard Bioscience
HBIO
|
1.89 M | $ 0.5 | -6.73 % | $ 21.2 M | USA |
 |
Glaukos Corporation
GKOS
|
-129 M | $ 119.29 | 0.28 % | $ 5.78 B | USA |
 |
Merit Medical Systems
MMSI
|
156 M | $ 80.93 | 0.85 % | $ 4.71 B | USA |
 |
Isoray
ISR
|
-90.9 M | - | 0.03 % | $ 108 M | USA |
 |
iRhythm Technologies
IRTC
|
-116 M | $ 154.21 | 3.5 % | $ 4.81 B | USA |
 |
LeMaitre Vascular
LMAT
|
52.3 M | $ 84.97 | 1.32 % | $ 1.91 B | USA |
 |
STERIS plc
STE
|
867 M | $ 261.9 | 0.02 % | $ 25.8 B | USA |
 |
Intuitive Surgical
ISRG
|
2.35 B | $ 505.17 | -0.47 % | $ 179 B | USA |
 |
NeuroMetrix
NURO
|
-8.78 M | - | 5.05 % | $ 9.02 M | USA |
 |
Microbot Medical
MBOT
|
-9.86 M | $ 1.81 | -2.96 % | $ 18.5 M |  Israel |
 |
Utah Medical Products
UTMD
|
16.8 M | $ 61.21 | -0.71 % | $ 222 M | USA |
 |
Nephros
NEPH
|
-1.59 M | $ 4.35 | -0.91 % | $ 45.2 M | USA |
 |
Milestone Scientific
MLSS
|
-6.76 M | $ 0.29 | -2.67 % | $ 23.1 M | USA |
 |
Envista Holdings Corporation
NVST
|
-1.04 B | $ 23.4 | 0.13 % | $ 4.03 B | USA |
 |
Pro-Dex
PDEX
|
10.7 M | $ 38.77 | -1.61 % | $ 127 M | USA |
 |
Predictive Oncology
POAI
|
-10.9 M | - | - | $ 31.1 M | USA |
 |
Pulse Biosciences
PLSE
|
-43.6 M | $ 13.76 | 0.99 % | $ 661 M | USA |
 |
Repligen Corporation
RGEN
|
47.7 M | $ 150.44 | -3.8 % | $ 8.38 M | USA |
 |
ResMed
RMD
|
1 B | $ 256.15 | -0.57 % | $ 37.4 B | USA |
 |
BioLife Solutions
BLFS
|
-7.13 M | $ 21.91 | -2.97 % | $ 1.01 B | USA |
 |
Stereotaxis
STXS
|
-21.8 M | $ 2.21 | -5.36 % | $ 178 M | USA |
 |
Retractable Technologies
RVP
|
-21.1 M | $ 0.7 | -1.03 % | $ 21 M | USA |
 |
STAAR Surgical Company
STAA
|
-12.6 M | $ 18.9 | -0.24 % | $ 928 M | USA |
 |
Teleflex Incorporated
TFX
|
151 M | $ 104.44 | -0.96 % | $ 4.89 B | USA |
 |
West Pharmaceutical Services
WST
|
570 M | $ 231.57 | -0.4 % | $ 16.9 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-879 M | $ 12.47 | 1.63 % | $ 2.53 B | USA |